LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Alvotech SA

Fechado

SetorSaúde

10.65 1.72

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.57

Máximo

10.7

Indicadores-chave

By Trading Economics

Rendimento

177M

110M

Vendas

-18M

133M

P/E

Médio do Setor

30.311

51.198

EPS

0.363

Margem de lucro

82.612

Funcionários

1,012

EBITDA

257M

137M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+166.67% upside

Dividendos

By Dow Jones

Próximos Ganhos

13 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

291M

3.4B

Abertura anterior

8.93

Fecho anterior

10.65

Sentimento de Notícias

By Acuity

9%

91%

8 / 380 Ranking em Healthcare

Alvotech SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de abr. de 2025, 14:54 UTC

Ganhos

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

Comparação entre Pares

Variação de preço

Alvotech SA Previsão

Preço-alvo

By TipRanks

166.67% parte superior

Previsão para 12 meses

Média 28 USD  166.67%

Máximo 28 USD

Mínimo 28 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Alvotech SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

8 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.